The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

SAN DIEGO, April 13, 2026 (GLOBE NEWSWIRE)-- Neomorph, Inc., a biotechnology company pioneering molecular glue degraders to address previously undruggable proteins, today announced the closing of a ...

SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Neomorph, Inc., a biotechnology company pioneering molecular glue degraders to address previously undruggable proteins, today announced the first patient ...

(RTTNews) - Biogen Inc. (BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer's, rare neurological, and ...

The collaboration aims to discover and develop molecular glue degrader clinical candidates for priority targets to Biogen. Collaboration leverages Neomorph's leading molecular glue discovery platform ...

Presentation in the New Drugs on the Horizon session to feature the development of NEO-811, a novel ARNT (HIF-1β)-targeted therapy in clear cell renal cell carcinoma (ccRCC) Three additional ...

SAN DIEGO--(BUSINESS WIRE)--Neomorph, Inc. announced a $109 million Series A financing to advance a proprietary targeted protein degradation platform and specific programs. Deerfield Management ...

SAN DIEGO--(BUSINESS WIRE)--Neomorph, Inc., a venture backed biotechnology company solving critical problems in human health through the discovery and development of innovative new medicines against ...

The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen by an independent group of researchers. The Nature Index provides absolute Count of ...

Financing will support the ongoing Phase 1/2 trial of NEO-811 for the treatment of locally advanced or metastatic non-resectable clear cell renal cell carcinoma (ccRCC) and the continued advancement ...